The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2019 | Targeting BCL-2 in older AML: novel venetoclax combinations
Treatment options for older patients with acute myeloid leukemia (AML) are growing increasingly important. Here, Andrew Wei, MBBS, PhD, of Alfred Hospital and Monash University, Melbourne, Australia, speaks with us about the latest data on venetoclax in this setting at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany. Dr Wei highlights the importance of specific mutations in determining response and how best to give venetoclax; for example, patients with TP53 mutations can be hard to treat but the novel agent APR-246 is being investigated in combination with venetoclax for this group.
